What is Shandong Xinhua Pharmaceutical Company Limited?
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally.
SHNXY · Verdict
Moderate reward · moderate risk
SHNXY stands out on volatility and growth, but watch the profitability signal.
Based on 88% data coverage
SHNXY · Verdict
Above average
Rev +8.9% CAGR · earnings +10.5%
6% net margin · 9% ROE
Current ratio 1.33
Model-based scoring. For information only — not financial advice.
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 2.00B, and a P/E ratio of 22.7x.
The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.